Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of M1-c6v1 in advanced or metastatic solid tumors
jRCT2063230079Phase 1Recruiting
- Sponsor
- Guangzhou Virotech Pharmaceutical
- Start
- May 2024
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VRT-106 in Nonhematologic neoplasms, sponsored by Guangzhou Virotech Pharmaceutical. Primary endpoints: Safety and tolerability; dose determination and Dose-limiting toxicities and adverse events. Started May 2024; status: recruiting.
02
Drugs
VRT-106
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2063230079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063230079.